Bimekizumab in Active AS_ 5 Year Study
Deep Neural Networks and Radiographic Progression in AxSpA
Difficult to Treat axSpA
From AS Patient to Rheumatologist
Imaging Updates in SpA
INVIGORATE-1 Study_ IV Secukinumab for Treatment of Active axSpA
Monitoring the Effect of Therapy with a...Smart Watch_
Overlap of Inflammatory and Degenerative Features in Radiographic axSpA
People with AxSpa Need More Sleep
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
SpA Insights_ New Therapies
Teledidactic vs On Campus Training in Musculoskeletal Ultrasound
Treatments in SpA
Undiagnosed IBD in AxSpA
Using Telemedicine to Improve Diagnosis of AxSpA
EULAR 2024 Daily Podcasts Day1&2
Predicting Palindromic Prognosis
A Step Closer to Identifying Phenotypes of RA ILD
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
Giant Cell Arteritis and Polymyalgia Rheumatica Update
JAK Inhibitors for New Indications
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
JAK Inhibitors for New Indications
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Treat to Target Outcomes in Early AxSpA
Does Telemonitoring in SpA Work?
PsA Treatment: is Earlier Better?
JAK Inhibitors for New Indications
Transition from Psoriasis to PsA: Can we Prevent It?
EULAR 2024 Daily Recap - Days 1 & 2
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive